ArticleAdvanced healthcare materials2024
The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation?
Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Beyond Conventional: A Review of Phytochemical-Hydrogel Systems Enhanced by AI and 3D Printing for Chronic Wound Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The expanding role of formulations to enable oral delivery of poorly water-soluble drugs.Nature reviews. Drug discovery · 2026Review
- Advances in hemostatic biomaterials: biomimetic strategies, nanotechnology, and smart therapeutics.Burns & trauma · 2026Review
- Precision-Guided Stealth Missiles in Biomedicine: Biological Carrier-Mediated Nanomedicine Hitchhiking Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Pharmaceutical technological trends containing flavonoids: a patent review.Future medicinal chemistry · 2025Review
- Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation.Frontiers in medical technology · 2025Review
- The Dawn of a New Pharmaceutical Epoch: Can AI and Robotics Reshape Drug Formulation?Advanced healthcare materials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Over the last four decades, pharmaceutical companies' expenditures on research and development have increased 51-fold. During this same time, clinical success rates for new drugs have remained unchanged at about 10 percent, predominantly due to lack of efficacy and/or safety concerns. This persistent problem underscores the need to innovate across the entire drug development process, particularly in drug formulation, which is often deprioritized and under-resourced.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.